AbbVie: 3 Key Takeaways for Long-Term Investors
· fool.com · popularity 16/100 · 0 similar stories today · Breaking & World News (World News & Media)
Read the original at fool.com →
Summary
Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety. On …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 19.